

A Functional Role of S100A4/Non-Muscle Myosin IIA Axis for Pro-Tumorigenic Vascular Functions in Glioblastoma

Madoca Inukai

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Ako Yokoi

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Yuuki Ishizuka

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Miki Hashimura

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Toshihide Matsumoto

Kitasato University: Kitasato Daigaku

Yasuko Oguri

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Mayu Nakagawa

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Yu Ishibashi

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Takashi Ito

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Toshihiro Kumabe

Kitasato University School of Medicine: Kitasato Daigaku Igakubu

Makoto Saegusa (✉ msaegusa@med.kitasato-u.ac.jp)

Kitasato Daigaku Igakubu <https://orcid.org/0000-0001-5366-7149>

Research

Keywords: glioblastoma, S100A4, non-muscle myosin IIA, hypoxia, recruitment, cell migration

Posted Date: December 20th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1160637/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Cell Communication and Signaling on April 7th, 2022. See the published version at <https://doi.org/10.1186/s12964-022-00848-w>.

Abstract

Background

Glioblastoma (GBM) is the most aggressive form of brain tumor and has vascular-rich features. The S100A4/non-muscle myosin IIA (NMIIA) axis contributes to aggressive phenotypes in a variety of human malignancies, but little is known about its involvement in GBM tumorigenesis. Herein, we examined the role of the S100A4/NMIIA axis during tumor progression and vasculogenesis in GBM

Methods

We performed immunohistochemistry for S100A4, NMIIA, and two hypoxic markers including hypoxia-inducible factor-1 α (HIF-1 α) and carbonic anhydrase 9 (CA9) in samples from 94 GBM cases. The functional impact of S100A4 knockdown and hypoxia were also assessed using a GBM cell line.

Results

In clinical GBM samples, overexpression of S100A4 and NMIIA was observed in both non-pseudopalisading (Ps) and Ps (-associated) perinecrotic lesions, consistent with stabilization of HIF-1 α and CA9. CD34(+) microvascular densities (MVDs) and the interaction of S100A4 and NMIIA were significantly higher in non-Ps perinecrotic lesions compared to those in Ps perinecrotic areas. In non-Ps perinecrotic lesions, S100A4(+)/HIF-1 α (-) GBM cells were recruited to the surface of host preexisting vessels in the vascular-rich areas. Elevated vascular endothelial growth factor A (VEGFA) mRNA expression was found in S100A4(+)/HIF-1 α (+) GBM cells adjacent to the vascular-rich areas. In addition, GBM patients with high S100A4 protein expression had significantly worse OS and PFS than did patients with low S100A4 expression. Knockdown of S100A4 in the GBM cell line KS-1 decreased migration capability, concomitant with decreased Slug expression; the opposite effects were elicited by blebbistatin-dependent inhibition of NMIIA.

Conclusion

S100A4(+)/HIF-1 α (-) GBM cells are recruited to (and migrate along) preexisting vessels through inhibition of NMIIA activity. This is likely stimulated by extracellular VEGF that is released by S100A4(+)/HIF-1 α (+) tumor cells in non-Ps perinecrotic lesions. In turn, these events engender tumor progression via acceleration of pro-tumorigenic vascular functions.

Background

Glioblastoma (GBM) is the most aggressive form of brain tumor with median overall survival of only 15.6 months with standard care (radiation and Temozolomide) and 20.5 months with additional treatment [1].

The tumor malignancy and clinical prognosis correlates with the vascular-rich features, which are characterized by vascular proliferation in response to abundant vascular endothelial growth factor (VEGF) produced by tumor cells [2, 3]. The tumor vessels are morphologically and functionally different from normal blood vessels, demonstrating tortuous, disorganized, highly permeable, and abnormal in the endothelial walls, pericyte coverage, and basal cell membrane [4].

Glioma stem cells (GSC), constitute a subset of tumorigenic cancer stem cells (CSC), can self-renew and reconstitute a phenocopy of the original tumor; they are putative drivers of GBM malignancy and progression [5, 6]. In general, GSC reside within specialized tumor microenvironments or niches that maintain their stemness and malignant properties. Such environments include perivascular regions, hypoxic areas (adjacent to necrotic zones), and invasive niches [6–8]. GSC play an important role in tumor angiogenesis by inducing the formation of vascular endothelial cells and pericytes that may actively remodel perivascular niches [9, 10].

The S100 protein family is comprised of multigene calcium-binding proteins of the EF-hand type and has more than 25 members, each encoded by separate gene clusters on chromosome 1q21 [11, 12]. Although S100 family members are highly identical at the sequence and structural level, they are not functionally interchangeable [13–15]. S100A4 is frequently overexpressed in a variety of human malignancies and drives metastasis by stimulating angiogenesis, promoting the migration of tumor cells, and by facilitating the adhesion of cells to the extracellular matrix [16–19]. Although S100A4 possesses no enzymatic activity, it exerts its effects by interacting with and modulating the activity of other proteins, such as p53, non-muscle myosin IIA (NMIIA), and Annexin 2 to enhance tumor progression [20].

Here, we tested the hypothesis that the S100A4/NMIIA axis might contribute to GBM progression through modulation of tumor vascularization. We investigated the association between S100A4 and NMIIA expression, as well as the profiles of hypoxia-related molecules, and tumor vascularization status using clinical samples and cell lines of GBM.

Methods

Clinical cases

We selected 94 cases of primary isocitrate dehydrogenase (IDH) 1-wild type GBM that were surgically resected at Kitasato University Hospital between 2008 and 2020. Selection was based on the criteria of the 2016 World Health Organization classification of tumors of the central nervous system [23]. The mean age of the patients was 58.9 years (range, 10—82 years). In GBM tissues, necrotic foci within tumor lesions were subdivided into two categories, including necrosis with or without pseudopalisading (Ps) lesions, which are characterized by an accumulation of tumor cells around central necrosis zone. Tumor lesions adjacent to non-Ps necrotic foci were also subdivided into three categories including adjacent, vascular-rich, and distant areas. None of the patients were treated with chemoradiation therapy before surgical resection of the tumors. All tissues were routinely fixed in 10% formalin and processed for

embedding in paraffin wax. Approval for this study was given by the Ethics Committee of the Kitasato University School of Medicine (B20-197).

Antibodies and reagents

Anti-hypoxia-inducible factor (HIF)-1 α and anti-aldehyde dehydrogenase (ALDH) 1 antibodies were purchased from BD Biosciences (San Jose, CA, USA). Anti-CD34, anti-CD44s, anti-glial fibrillary acid protein (GFAP), and anti-human smooth muscle actin (SMA) antibodies were obtained from Dako (Copenhagen, Denmark). Anti-Snail and anti-Slug antibodies were from Cell Signaling Technology (Danvers, MA, USA). Anti-Sox2, anti-S100A4 (rabbit), anti-Twist 1, anti-Nestin, and anti-CD44v6 antibodies were obtained from Abcam (Cambridge, MA, USA). Anti-S100A4 (mouse), anti-carbonic anhydrase (CA) 9, and anti-NMIIA antibodies were from Proteintech (Rosemont, IL, USA). Anti-ZEB 1 and anti- β -actin antibodies were from Sigma-Aldrich Chemicals (St Louis, MA, USA). Blebbistatin and cobalt chloride (CoCl₂) were purchased from Toronto Research Chemicals (North York, ON, Canada) and Sigma Chemical, respectively.

Immunohistochemistry (IHC)

IHC was performed using a combination of the microwave-oven heating and polymer immunocomplex (Envision, Dako) methods as described previously [24–26].

For evaluation of IHC findings, scoring of nuclear or cytoplasmic immunoreactivities was performed as described previously [24–26]. Briefly, the proportion of immunopositive cells among the total number of counted cells was subdivided into five categories as follows: 0, all negative; 1, <10%; 2, 10—30%; 3, 30—50%, and 4, >50% positive cells. The immunointensity was also subclassified into four groups: 0, negative; 1, weak; 2, moderate, and 3, strong. IHC scores were generated by multiplication of the values of the two parameters. CD34 immunopositive vessels were also counted in five randomly selected high-power fields (HPFs). Microvascular density (MVD) was then calculated as an HPF.

Immunofluorescence

The slides were heated in 10 mM citrate buffer (pH 6.0) for 3 x 5-min cycles using a microwave oven and then incubated overnight with anti-S100A4, anti-SMA, and anti-GFAP antibodies. Alexa 488, 570, and 647 (Thermo Fisher Scientific, Waltham, MA, USA) were used as secondary antibodies.

In situ Proximity ligation assay (PLA)

The slides were heated in 10 mM Tris-EDTA buffer (pH 9.0) for 3 x 5-min cycles using a microwave oven and then incubated overnight with anti-S100A4 (mouse) and anti-NMIIA (rabbit) antibodies. PLA was

carried out the Duolink Detection kit with proximity ligation assay PLUS and MINUS probes for mouse and rabbit (Olink Bioscience, Uppsala, Sweden) as described previously [26]. The PLA signal score was determined on the basis of the percentage of PLA signal-positive cells and the PLA signal intensity with the multiplication of values of the two parameters as described previously [26].

RNAscope assay for VEGFA mRNA in situ hybridization

VEGFA mRNA expression was analyzed using an RNAscope assay (Advanced Cell Diagnostics, Hayward, CA, USA) according to manufacturer's instructions. Briefly, deparaffined sections were incubated with the target retrieval for 15 min at 98°C and were then treated by proteinase Plus for 30 min at 40°C. The hybridization was performed with targeted probes: Hs-VEGFA (#423161), positive control probe (#2010684), and negative control probe (#310043) for 2 h at 40°C. The signals were visualized with 3,3'-diaminobenzidine and the nuclei were counterstained with methyl -green.

Reverse transcription (RT)-PCR

cDNA was synthesized from 2 µg of total RNA. Amplification by RT-PCR was carried out in the exponential phase to allow comparison among cDNAs synthesized from identical reactions using specific primers. Primers for the *S100A4*, *VEGFA* and *GAPDH* genes were used as described previously [24–26].

Plasmids and cell line

S100A4-specific shRNA, pGL3B(-1976/+1012) S100A4-luc, pGL3B(-2000/+50) VEGFA luc, and pcDNA3.1-HIF-1α were used as described previously [24–27]. GBM cell line KS-1 was obtained from the Health Science Research Resources Bank (Osaka, Japan) and was maintained in Eagle's MEM with 10% bovine calf serum. S100A4-knockdown (KD) KS-1 cells (which have relatively high S100A4 expression) were established using an shRNA targeting the *S100A4* gene as described previously [25, 26]. For hypoxia experiments, cells were treated with 100 and/or 200 µM CoCl₂ under 5% CO₂ at 37°C as described previously [28].

Western blot assay and co-immunoprecipitation (IP)

Total cellular proteins were isolated using RIPA buffer [20 mM Tris-HCl (pH 7.2), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate]. Aliquots of the proteins were resolved by SDS-PAGE, transferred to membranes, and probed with primary antibodies that were then coupled with the ECL detection system (Amersham Pharmacia Biotech., Tokyo, Japan).

For co-IP, cells were lysed with IP buffer [10 mM Tris-HCl (pH 7.6), 100 mM NaCl, and 10% NP-40] in the presence of 1 mM CaCl₂. Cell lysates were cleared and incubated with anti-S100A4 and NMIIA antibodies, followed by incubation with Protein G-Sepharose (Amersham Pharmacia Biotech). Western blot assay was subsequently performed with anti-S100A4 and anti-NMIIA antibodies.

Aldefluor assay

ALDH 1 enzyme activity in viable cells was determined using a fluorogenic dye-based Aldefluor assay (Stem Cell Technologies, Grenoble, France), according to the manufacturer's instructions. The prepared cells were analyzed by flow cytometry using BD FACS Calibur (BD Biosciences) and CellQuest Pro software (BD Biosciences).

Spheroid assay

Cells (1×10^3) were plated in low cell binding plates (Thermo Fisher Scientific, Yokohama, Japan) in Neuralbasal medium (Thermo Fisher Scientific, Waltham, MA, USA). Uniform spheroids with a minimum diameter of 50 μ m were counted approximately two weeks following plating.

Wound healing assay

Cells were seeded into 24-well tissue culture plates and grown to reach almost total confluence. After a cell monolayer formed, a scratch wound was made with a sterile 200- μ l tip. The area of the wound was analyzed with ImageJ software version 1.41 (NIH). Cell migration was calculated based on the number of pixels occupied by the wound closure compared to control scratches.

Migration assay

Cell migration was determined using 24-well transwell chambers with 8- μ m pore size (Corning, NY, USA). The lower chamber was filled with medium containing 10% serum. Cells were suspended in the serum-free upper medium and transferred into the upper chamber. After 48 h, the number of HE-stained cells on the bottom surface of the polycarbonate membranes was counted using a light microscope.

TCGA data analysis

mRNA expression data (RNA Seq V2 PSEM) for the *S100A4* and *myosin heavy chain (MYH) 9* (also known as NMIIA) genes in 144 GBM cases were extracted from cBioportal for Cancer Genomics (<http://www.cbioportal.org/>). The data were subcategorized into 'high' and 'low' groups (scores >0 and 0,

respectively) based on the median Z score (= 0) for mRNA expression levels in each category, and then examined for any correlation with overall survival (OS) or progression-free survival (PFS).

Statistics

Comparative data were analyzed using the Mann-Whitney *U*-test and the Spearman's correlation coefficient. Overall survival (OS) was calculated as the time between onset and death of the date or the last follow-up evaluation. Progression-free survival (PFS) was also examined from the onset of treatment until relapse, disease progression, or last follow-up evaluation. OS and PFS were estimated using the Kaplan-Meier method, and statistical comparisons were made using the log-rank test. Univariate analysis was also performed using the Cox proportion hazards regression model. The cutoff for statistical significance was set as $P < 0.05$.

Results

Overexpression of S100A4 in response to hypoxic effects in GBMs

Representative images of IHC findings for S100A4, NMIIA, HIF-1 α , and CA9 in GBMs are illustrated in Figure 1A. Nuclear/cytoplasmic immunoreactivity for S100A4, nuclear immunoreactivity for HIF-1 α , and cytoplasmic immunostaining for NMIIA and CA9 were frequently found in GBM cells that were mainly located at both non-Ps and Ps (-associated) perinecrotic lesions. Average IHC scores for these markers were significantly higher in non-Ps perinecrotic and Ps lesions when compared to those of non-necrotic tumor areas (Figure 1B). In addition, S100A4 score was positively correlated with NMIIA, HIF-1 α , and CA9 scores. NMIIA score was also positively correlated with HIF-1 α and CA9 scores (Table 1).

In KS-1 cells, treatment with the hypoxia mimetic CoCl₂ increased the expression of S100A4 and HIF-1 α (Figure 1C); consistent with this, the expression of S100A4 mRNA was increased. A search of the *S100A4* promoter for potential HIF-1 α binding sites (a consensus core motif of 5'-A/GCGTG-3') revealed the presence of three sites, at -1959 to 1950, -1838 to -1829, and -1785 to -1776 (Figure 1D), as well as +329 to +334 site in the first intron as previously reported [29]. The long (-1976/+1012) *S100A4* promoter construct was activated ≈ 1.6 fold following transfection of HIF-1 α , whereas such an effect was not evident in short (-447/+1012) *S100A4* promoter (Figure 1E).

These findings suggest that increased S100A4 expression, which is at least partly driven by HIF-1 α -transactivation, is found in perinecrotic lesions of GBM tissues under hypoxic conditions.

S100A4 is associated with cell migration through an interaction with NMIIA

To examine whether S100A4 contributes to GBM cell migration, we established two independent KS-1 cell line clones in which S100A4 expression was blocked by S100A4-specific shRNAs (KS-shS100A4#3 and #5). Expression of Slug, but not Snail, Twist1, or ZEB1, was reduced in KS-S100A4-knockdown (KD) cells when compared to control cells (Figure 2A). The KS-S100A4-KD cells refilled wounded empty spaces more slowly (Figure 2B), in line with their significantly decreased migration rates as compared with control cells (Figure 2C).

Because the biological activity of S100A4 is based on interactions with potential binding partners [20], we evaluated the function of NMIIA, a major partner for S100A4 [20], in KS-1 cells. To this end, we used blebbistatin, a synthetic chemical compound that effectively and reversibly blocks the ATPase activity of NMII without inhibiting class I, V, and X myosin superfamilies [30]. Treatment with the compound significantly enhanced cellular migration capacity in a dose-dependent manner (Figure 2D).

To further examine the interaction between S100A4 and NMIIA, we performed an in situ PLA assay using antibodies targeting S100A4 and NMIIA in 10 GBM cases. Interactions of the two molecules were predominantly observed in the cytoplasmic compartments of GBM cells. The PLA score was significantly higher in non-Ps perinecrotic lesions when compared to those of Ps lesions and non-necrotic tumor areas (Figure 2E). This association was confirmed by co-IP of S100A4 and NMIIA in KS-1 cells (Supplementary Figure S1).

Since S100A4 is a normal stemness marker [31, 32], we also examined whether there were an association between S100A4 and GSC properties. Immunoreactivity for Nestin, which is a neuronal stem cell marker [3], was significantly higher in non-Ps and Ps perinecrotic lesions as compared to non-necrotic areas in GBM tissues (Supplementary Figure S2A). Nestin expression was also positively correlated with S100A4, NMIIA, HIF-1 α , and CA9 scores (Table 1). Treatment of KS-1 cells with CoCl₂ increased the expression of Nestin and HIF-1 α (Supplementary Figure S2B). However, S100A4-KD did not alter the expression of several CSC-related markers, spheroid formation, or ALDH1^{high} population (Supplementary Figure S2C, D, E).

These findings suggest that S100A4 enhances cell mobility via inhibition of NMIIA, but does not regulate GSC properties in KS-1 cells.

S100A4 is associated with vascularization in non-Ps perinecrotic lesions of GBM

Since activation of HIF-1 signaling contributes to the intense vascular hyperplasia often seen in GBM [33], we first examined vascular status in both non-Ps and Ps perinecrotic lesions. CD34(+) small vessels were frequently observed in non-Ps perinecrotic lesions when compared to those of Ps perinecrotic and non-necrotic lesions (Figure 3A). The differences in microvascular densities (MVDs) as determined by CD34 immunohistochemistry were statistically significant (Figure 3A).

Based on the above findings, we subdivided non-Ps perinecrotic lesions into three categories: those adjacent to massive necrotic areas within tumors, vascular-rich lesions, and distant lesions (Figure 3B). MVDs were significantly higher in vascular-rich areas when compared to those of adjacent and distant lesions. S100A4 and NMIIA scores were significantly higher in both adjacent and vascular-rich areas compared to distant lesions, whereas HIF-1 α and CA9 scores were significantly higher in adjacent lesions than in vascular-rich and distant lesions (Figure 3C).

Finally, strong S100A4(+)/GFAP(+) GBM cells showed vessel co-option, where tumor cells migrate along the preexisting vessel [34], around both small- and mature vascular structures with strong SMA(+) vascular components in the vascular-rich area (Figure 4A). In contrast, tumor cells expressing VEGFA mRNA, along with nuclear HIF-1 α , were found in adjacent, but not vascular, lesions (Figure 4B). In KS-1 cells, treatment with CoCl₂ increased VEGFA mRNA expression, consistent with activation of the *VEGFA* promoter following cotransfection of HIF-1 α (Figure 4C).

These findings suggest that S100A4(+)/HIF-1 α (-) GBM cells are co-opted along preexisting vessels in the vascular-rich area; they are adjacent to S100A4(+)/HIF-1 α (+) tumor cells with activated HIF-1 α /VEGF signaling in non-Ps perinecrotic lesions.

S100A4 is associated with unfavorable prognosis in GBM

To evaluate the prognostic significance of S100A4 and its related markers, the IHC scores were divided into two categories (high and low) based on the cut-off values (mean scores) (Table 2). Kaplan-Meier analysis revealed that, in GBM cases, patients with high S100A4 scores had poorer OS and PFS when compared to patients with low scores, but such associations were not observed with regard to NMIIA scores (Figure 5A). We made similar observations when we analyzed the TCGA data for expression of S100A4 and MYH9 (NMIIA) mRNA (Figure 5B). Of five IHC markers and two clinical factors, univariate Cox progression hazards regression revealed that only S100A4 score was a significant prognostic factors for OS and PFS in GBM (Table 2).

Discussion

The present study clearly provides evidence that overexpression of S100A4, as well as NMIIA, occurs in both non-PS and Ps perinecrotic lesions and is positively correlated with HIF-1 α and CA9 expression in GBM; these findings are consistent with those of other studies in esophageal and gastric carcinomas [29, 35]. Inducing hypoxia in KS-1 cells led to the upregulation of S100A4 at both the mRNA and protein level, in line with stabilization of HIF-1 α protein. In addition, we demonstrated that HIF-1 α can specifically activate transcription of an *S100A4* promoter reporter; this is contrast to earlier study that used a gastric carcinoma cell line [29]. One possible reason for the discrepant results may be that transactivation of *S100A4* requires cell type-specific factors.

Interestingly, S100A4(+)/HIF-1 α (+) GBM cells were found near non-Ps perinecrotic lesions, whereas S100A4(+)/HIF-1 α (-) tumor cells were located at the adjacent vascular-rich areas. Since *S100A4* is

transcriptionally upregulated through hypoxia-induced activation of NF- κ B signaling [25, 36, 37], it appears that the regulation of S100A4 expression in hypoxic regions of GBM is multifactorial. In fact, STAT3 works with HIF1 to activate HIF1 target genes and to drive HIF-1-dependent tumorigenesis under hypoxic conditions [38].

We also found that S100A4 knockdown was closely associated with decreased migration capability, along with reduced Slug expression, which is a major indicator for epithelial-mesenchymal transition [39]. The opposite effects were elicited following blebbistatin-dependent inhibition of NMIIA activity. An interaction between S100A4 and NMIIA was observed in lysates from KS-1 cells, and by using in situ PLA we confirmed that this interaction was mainly in the cytoplasm of tumor cells, particularly in non-Ps perinecrotic lesions. Because S100A4 can abrogate the actin-dependent ATPase and polymerization activity of NMIIA [40, 41], S100A4 may serve as a critical regulator of tumor migration, in line with the idea that NMIIA acts as an inhibitor of cell migration [42]. Furthermore, the PLA score was significantly higher in non-Ps perinecrotic lesions, which suggests these lesions may harbor other microenvironmental factors associated with tumor migration ability. Further studies will be required in order to elucidate these factors.

Importantly, S100A4(+)/HIF-1 α (-) tumor cells were recruited along the surface of host preexisting vessels in vascular-rich areas of non-Ps perinecrotic lesions, whereas high VEGFA mRNA expression was found in S100A4(+)/HIF-1 α (+) GBM cells in the adjacent areas. Although co-opting host vessels is just one strategy that tumor can employ to survive, it can be essential in some instance [43]. The expression of recombinant VEGF-A₁₆₅ alters the architecture and function of the co-opted preexisting brain vasculature in melanoma brain metastases [44]. Similarly, therefore, we suggest that S100A4-driven alteration of preexisting vasculature may play a critical role in GBM progression, perhaps by accessing an alternative tumor blood supply in the presence of VEGFA. This hypothesis is supported by data herein showing that high S100A4 expression was associated with significantly worse OS and PFS than low S100A4 expression, and by the results of our TGCA data analysis.

Finally, high Nestin score was significantly associated with hypoxia in GBM tissues, as well as in the KS-1 cell line, which is consistent with reports of an increased CSC fraction and acquisition of a stem-like state following oxygen deprivation [5, 6]. Since S100A4 and Nestin scores are positively correlated in GBM and S100A4 is reportedly a critical regulator of the epithelial to mesenchymal transition in GSC [45], we predicted that S100A4 may be a critical regulator of GSC. However, S100A4 knockdown did not elicit changes in several GSC properties. We therefore suggest that the role of S100A4 in modulation of GSC features is only manifest when S100A4 is overexpressed.

Conclusion

Our results suggest a novel functional role of the S100A4/NMIIA axis in GBM (Figure 6). Following severe hypoxia, S100A4 is upregulated and interacts with NMIIA; this inhibits NMIIA activity and thus derepresses tumor cell migration. S100A4(+)/HIF-1 α (-) tumor cells are subsequently recruited to, and

migrate along, preexisting vessels in the presence of extracellular VEGF released by S100A4(+)/HIF-1 α (+) GBM cells. This in turn results in tumor progression through acceleration of vascularization.

Abbreviations

GBM: glioblastoma; Ps: pseudopalisading; VEGF: vascular endothelial growth factor; GSC: glioma stem cell; NMIIA: non-muscle myosin IIA; HIF: hypoxia-inducible factor; ALDH: aldehyde dehydrogenase; GFAP: glial fibrillary acid protein; SMA: smooth muscle actin; CA9: carbonic anhydrase 9; CoCl₂: cobalt chloride; IP: immunoprecipitation; MYH9: myosin heavy chain 9; KD: knockdown; HE: hematoxylin and eosin; IHC; immunohistochemistry; OS: overall survival; PFS: progression-free survival; MVD: microvascular density

Declarations

Ethics approval and consent to participate

Approval for this study was given by the Ethics Committee of the Kitasato University School of Medicine (B20-197).

Consent for publication

Not applicable

Availability of data and materials

Data and materials will be shared.

Competing interests

The authors declare that they have no competing interest.

Funding

This study was supported by a grant from JSPS KAKENHI Grant Number 19K07421.

Authors' contributions

MI, AY, YI, and MS carried out the majority of the experiments, analyzed the data, and wrote the manuscript. They were helped by MH, MT, YO, MN, YI, TI, and TK. All authors reviewed and approved the final manuscript.

References

1. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu J-J, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND,

- Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbah A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. *JAMA*. 2015;314:2535-43.
2. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. *Cancer Res*. 1996;56:2671-6.
 3. Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. *World J Gastroenterol*. 2013;19:42-8.
 4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. *Nat Rev Neurosci*. 2007;8:610-22.
 5. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjemeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer Cell*. 2009;15:501-23.
 6. Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma: microenvironment and niche concept. *Cancers*. 2019;11:5.
 7. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakhararenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. *Cancer Cell*. 2007;11:69-82.
 8. Brooks LJ, Parrinello S. Vascular regulation of glioma stem-like cells: a balancing act. *Curr Opin Neurobiol*. 2017;47:8-15.
 9. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. *Proc Natl Acad Sci USA*. 2011;108:4274-80.
 10. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. *Cell*. 2013;153:139-52.
 11. Wang T, Huo X, Chong Z, Khan H, Liu R, Wang T. A review of S100 protein family in lung cancer. *Clinica Chimica Acta*. 2018;476:54-9.
 12. Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. *Biochim Biophys Acta Mol Cell Res*. 2020;1867:118677.
 13. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. *Am J Cancer Res*. 2014;4:89-115.
 14. Salama I, Malone PS, Mihaimed F, Jones JL. A review of the S100 proteins in cancer. *Eur J Surg Oncol* 2008;34:357-64.
 15. Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. *Nat Rev Cancer*. 2015;15:96-109.
 16. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Krajevska M, Tulchinsky E, georgiev G, Berezin V, Bock E, Rygaard J, Cao Y, Lukanidin E. The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. *Oncogene*. 2001;20:4685-95.

17. Oslejskova L, Grigorian M, Gay S, Neidhart M, Senolt L. The metastasis associated protein S100A4: a potential novel link to inflammation and consequent aggressive behavior of rheumatoid arthritis synovial fibroblasts. *Ann Rheum Dis.* 2008;67:1499-504.
18. Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B. Functional significance of metastasis-inducing S100A4 (Mts1) in tumor-stroma interplay. *J Biol Chem.* 2004;279:24498-504.
19. Novitskaya V, Grigorian M, Kriajevska M, Tarbykina S, Bronstein I, Berezin V, Bock E, Lukanidin E. Oligomeric forms of the metastasis-related MTS1 (S100A4) protein stimulate neuronal differentiation un cluteres of rat hippocampal neurons. *J Biol Chem.* 2000;275:41278-86.
20. Fei F, Qu J, Zhang M, Li Y, Zhang S. S100A4 in cancer progression and metastasis: a systematic review. *Oncotarget.* 2017;8:73219-39.
21. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N. Extracellular S100A4 (mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. *Oncogene.* 2004;23:5487-95.
22. Semov A, Moreno MJ, Onichtchenko A, Abulrov A, Ball M, Ekiel I, Pietryzynski G, Stanimirovic D, Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. *J Biol Chem.* 2005;280:20833-41.
23. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* 2016;131:803-820.
24. Chiba R, Akiya M, Hashimura M, Oguri Y, Inukai Madoka, Hara A, Saegusa M. ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation. *PLoS One.* 2017;12:e0183516.
25. Tochimoto M, Oguri Y, Hashimura M, Konno R, Matsumoto T, Yokoi A, Koderia Y, Saegusa M. S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. *Lab Invest.* 2020;100:682-95.
26. Hiruta A, Oguri Y, Yokoi A, Matsumoto T, Tomohiro M, Hashimura M, Jiang Z, Tochimoto M, Nakagawa M, Saegusa M. S100A4/nonmuscle myosin IIA/p53 axis contributes to aggressive features in ovarian high-grade serous carcinoma. *Am J Pathol.* 2020;190:2304-16.
27. Yoshida T, Hashimura M, Matsumoto T, Tazo Y, Inoue H, Kuwata T, Saegusa M. Transcriptional upregulation of HIF-1a by NF-kB/p65 and its associations with b-catenin/p300 complexes in endometrial carcinoma cells. *Lab Invest.* 2013;93:1184-93.
28. Inukai M, Hara A, Ysui M, Kumabe T, Matsumoto T, Saegusa M. Hypoxia-mediated cancer stem cells in pseudopalisades with activation of hypoxia-inducible factor-1a/Akt axis in glioblastoma. *Hum Pathol.* 2015;46:1496-1505.
29. Zhang R, Fu H, Chen D, Hua J, Hu Y, Sun K, Sun X. Subcellular distribution of S100A4 and its transcriptional regulation under hypoxic conditions in gastric cancer cell line BGC823. *Cancer Sci.* 2010;101:1141-6.

30. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR, Mitchison T. Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. *Science*. 2003;299:1743-1747.
31. Ito M, Kizawa K. Expression of calcium-binding S100 proteins A4 and A6 in regions of the epithelial sac associated with the onset of hair follicle regeneration. *J Invest Dermatol*. 2001;116:956-63.
32. Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin J, Sawicki JA, Cotsarelis G. Capturing and profiling adult hair follicle stem cells. *Nat Biotechnol*. 2004;22:411-7.
33. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. *Neuro-Oncol*. 2005;7:134-53.
34. Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter KC, Pezzella F. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? *Cancer Med*. 2013;2:427-36.
35. Xuan X, Li Q, Zhang Z, Du Y, Liu P. increased expression levels of S100A4 associated with hypoxia-induced invasion and metastasis in esophageal squamous cell cancer. *Tumour Biol*. 2014;35:12535-43.
36. Xing Y, Wang R, Chen D, Mao J, Shi R, Wu Z, Kang J, Tian W, Zhang C. Cox2 is involved in hypoxia-induced TNF-a expression in osteoblast. *Sci Rep*. 2015;5:10020.
37. Mingyuan X, Qianqian P, Shengquan X, Chenyi Y, Rui L, Yichen S, Jinghong X. Hypoxia-inducible factor-1a activates transforming growth factor-b1/Smad signaling and increases collagen deposition in dermal fibroblasts. *Oncotarget*. 2018;9:3188-97.
38. Pawlus M, Wang L, Hu C-J. STAT3 and HIF1a cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. *Oncogene*. 2014;33:1670-9.
39. Li Z-H, Bresnick AR. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. *Cancer Res*. 2006;66:5173-80.
40. Kriajevska M, Tarabykina S, Bronstein I, Maitland N, Lomonosov M, Hansen K, Gergiev G, Lukanidin E. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin J *Biol Chem*. 1998;273:9852-6.
41. Ouderkirk JL, Krendel M. Non-muscle myosins in tumor progression, cancer cell invasion and metastasis. *Cytoskeleton (Hoboken)*. 2014;71:447-63.
42. Hajra KM, Chen DY, Fearon ER. The Slug zinc-finger protein represses E-cadherin in breast cancer. *Cancer Res*. 2002;62:1613-8.
43. Zhao C, Yang H, Shi H, Wang X, Chen X, Yuan Y, Lin S, Wei Y. Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and mirometastasis. *Carcinogenesis*. 2011;32:1143-50.
44. Kusters B, Leenders WPJ, Wesseling P, Smits D, Verijp K, Ruiters DJ, Peters JPW van der Kogel AJ, de Wall RMW. Vascular endothelial growth factor-A₁₆₅ induces progression of melanoma brain metastases without induction of sprouting angiogenesis. *Cancer Res*. 2002;62:341-5.

45. Chow K-H, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. *Cancer Res.* 2017;77:5360-73.

Tables

Due to technical limitations, tables are only available as a download in the Supplemental Files section.

Figures




Figure 1

Overexpression of S100A4 under hypoxic conditions in GBMs.

(A) Staining by HE and IHC for the indicated proteins in GBMs. Note the strong immunoreactivity for S100A4, NMIIA, HIF-1 α , and CA9 in both non-Ps and Ps perinecrotic lesions. Necrotic areas are indicated by asterisks and partitioned by dotted lines. Insets show the magnified views of the boxed area. Original magnification, x100 and x400 (inset). (B) IHC score for the indicated molecules in non-Ps and Ps perinecrotic (non-Ps and Ps) and non-necrotic lesions (non-nec). The data are presented as means \pm SDs. (C) Western blot (left) and RT-PCR analyses (right) for the indicated molecules in total lysates or total RNA from KS-1 cells treated with 100 and 200 mM CoCl₂ for 24 h. (D) The *S100A4* promoter sequence containing four putative HIF-1 α -binding sites (BEs). (E) KS-1 cells were transfected with long (-1986/+1012) and short (-447/+1012) *S100A4*-luc reporter constructs, together with HIF-1 α . Relative

activity was determined based on arbitrary luciferase light units normalized to pRL-TK activity. The activities of the reporter plus the effector relative to that of the reporter plus empty vector are shown as means \pm SDs. The experiment was performed in duplicate.




Figure 2

Changes in cell migration ability following knockdown of S100A4 and inhibition of NMIIA activity in GBM cells. (A) Western blot analysis for the indicated proteins of total lysates from S100A4-knockdown KS-1 (KS-shS100A4#3 and #5) and control cells (Con). (B) Left: wound-healing assay with S100A4-knockdown KS-1 and control cells (Con). A scratch was made in the middle of confluent cells, and phase-contrast images were taken after 0 h (upper), 24 h (middle) and 48 h (lower). Right: wound area values were calculated using NIH ImageJ software, with those at 0 h set as 1. The fold wound areas are presented as means \pm SDs. (C) Left: migration rate measured using a transwell assay. The S100A4-knockdown KS-1 and control cells (Con) were seeded in a 24-well transwell plate and incubated for 24 h in medium without serum. Cells were stained by HE and counted using a light microscope. Right: cell numbers are presented as means \pm SDs (lower). (D) Left: KS-1 cells were seeded in a 24-well transwell plate and incubated for 24 h in serum-free medium with 0, 2, 4, and 6 mM blebbistatin. Cells were stained by HE and counted using a light microscope. Right: cell numbers are presented as means \pm SDs. (E) Left and middle: in situ PLA assay for the S100A4-NMIIA interaction in non-Ps and Ps perinecrotic lesions of GBMs. Note the small aggregated dots in cytoplasmic and nuclear compartments of the GBM cells in non-Ps, but not Ps, perinecrotic lesions. Necrotic areas are indicated by asterisks and partitioned by dotted lines. Insets show the magnified views of the boxed area. Original magnification, x100 and x400

(inset). Right: PLA score for the combinations of S100A4 and NMIIA in non-Ps and Ps perinecrotic (non-Ps and Ps) and non-necrotic lesions (non). The data are presented as means \pm SDs.




Figure 3

Association between S100A4 expression and vascularization in GBM. (A) Upper: HE staining and IHC for CD34 in non-Ps and Ps perinecrotic (perinec) and non-necrotic lesions (non-nec) of GBMs. Note the dense CD34 immunoreactivity (closed circle) in non-Ps perinecrotic lesions, in contrast to the scattered immunopositivity (indicated by arrows) in Ps perinecrotic and non-necrotic lesions (non-nec). Necrotic areas are indicated by asterisks and partitioned by dotted lines. Original magnification, x100. Lower: microvascular density (MVD) determined by CD34 immunoreactivity in non-Ps and Ps perinecrotic (perinec) and non-necrotic lesions (non-nec). The data are presented as means \pm SDs. (B) Left: staining by HE and IHC for the indicated molecules in adjacent, vascular-rich, and distant areas of non-Ps perinecrotic lesions of GBMs. The three lesions are partitioned by dotted lines. Necrotic areas are indicated by asterisks. Insets show the magnified views of the boxed area. Original magnification, x100 and x400 (inset). Right: microvascular density (MVD) determined by CD34 immunoreactivity (upper) and IHC score for the indicated molecules in adjacent (adj), vascular-rich (vas), and distant (dis) areas of non-Ps perinecrotic lesions of GBMs. The data are presented as means \pm SDs.




Figure 4

Vascular co-option by S100A4-positive GBM cells and VEGFA mRNA expression in HIF-1a-positive tumor cells. (A) Staining by HE and IHC (upper) and immunofluorescence (middle and lower) for the indicated proteins in vascular-rich area of non-Ps perinecrotic lesions in GBMs. Upper: S100A4-positive GBM cells that are co-opted along the surface of preexisting small (indicated by boxes) and mature vessels (indicated by arrows). Middle and lower: S100A4/GFAP-positive GBM cells around both small (middle panels: indicated by boxes) and mature vessels (lower panels: indicated by arrows) along SMA-positive vascular components. Original magnification, x200. (B) Staining by HE (left), RNAscope for VEGFA mRNA (middle), and IHC for HIF-1a (right) in non-Ps perinecrotic lesions of GBM. Note the dense vascular structures (indicated by arrows) in the vascular-rich area (left) and the high VEGFA mRNA and HIF-1a immunopositivity in GBM cells in the adjacent area (partitioned by dotted lines) (middle and right). Necrotic areas are indicated by asterisks and partitioned by dotted lines. Insets show the magnified views of the boxed area. Original magnification, x100 and x400 (inset). (C) Left: RT-PCR analysis of VEGFA mRNA levels in KS-1 cells after 50 and 100 mM CoCl₂ treatment for 24 h. Right: KS-1 cells were transfected with VEGFA-luc reporter constructs, together with 100 and 250 ng HIF-1a. Relative activity was determined based on arbitrary luciferase light units normalized to pRL-TK activity. The activities of the reporter plus the effector relative to that of the reporter plus empty vector are shown as means \pm SDs. The experiment was performed in duplicate.




Figure 5

Relationship of S100A4 and NMIIA expression with prognosis in GBMs. (A) OS (left) and PFS (right) as a function of S100A4 and NMIIA protein expression (upper and lower) in GBM. (B) TCGA data analyses for OS (left) and PFS (right) as a function of S100A4 and NMIIA mRNA expression (upper and lower) in the GBMs.




Figure 6

Schematic representation of the role of the S100A4/NMIIA axis in GBM. Aggressive and poor prognostic features are elicited through enhancement of tumor cell mobility and acceleration of vascularization.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupFigureS1.tif](#)
- [SupFigureS2.tif](#)
- [Table1.xlsx](#)
- [Table2xlsx.xlsx](#)